Corrigendum: Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic (Frontiers in Oncology, (2019), 8, (652), 10.3389/fonc.2018.00652)

Pooja Ghatalia, Chad H. Smith, Arthur Winer, Jiangtao Gou, Lesli A. Kiedrowski, Michael Slifker, Patricia D. Saltzberg, Nicole Bubes, Fern M. Anari, Vineela Kasireddy, Asya Varshavsky, Yang Liu, Eric A. Ross, Wafik S. El-Deiry

Research output: Contribution to journalComment/debate

Abstract

[This corrects the article DOI: 10.3389/fonc.2018.00652.].

Original languageEnglish
Article number674782
Pages (from-to)674782
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - May 7 2021

Keywords

  • cfDNA
  • drug resistance
  • liquid biopsy
  • molecular target
  • precision oncology
  • tumor burden
  • tumor heterogeneity

Fingerprint

Dive into the research topics of 'Corrigendum: Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic (Frontiers in Oncology, (2019), 8, (652), 10.3389/fonc.2018.00652)'. Together they form a unique fingerprint.

Cite this